한글목차

치료용핵약품 시장 규모는 최근 급성장하고 있습니다. 2025년 21억 9,000만 달러에서 2026년에는 25억 1,000만 달러에 이르고, CAGR 14.5%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 암 발병률 증가, 갑상선 질환에 대한 요오드131의 조기 도입, 표적 암 치료제의 제한적인 가용성, 핵의학 부문의 확대, 방사성의약품의 임상적 수용성 향상에 기인하는 것으로 보입니다.

치료용핵약품 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 42억 7,000만 달러에 이르고, CAGR은 14.3%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 신규 치료용 동위원소 개발, 정밀 암 치료 접근법 확대, 핵의학 인프라에 대한 투자 증가, 방사성 리간드 요법 임상시험 증가, 표적 핵의학 의약품에 대한 규제 당국의 승인 촉진 등을 들 수 있습니다. 예측 기간 동안 주요 동향으로는 표적 방사성의약품 치료의 도입 증가, 루테튬177 및 알파선 방출 동위원소 사용 확대, 암 특이적 핵약물 응용 분야의 성장, 핵약물 병용요법 확대, 안전선량 측정 및 규제 준수에 대한 집중도 강화 등이 있습니다.

암 발병률 증가는 향후 몇 년 동안 치료용 핵의약품 시장의 성장을 견인할 것으로 예측됩니다. 암은 비정상적인 세포의 통제할 수 없는 증식과 확산을 특징으로 하는 질환입니다. 암 발생률 증가는 암 발견 및 진단 능력의 향상, 생활습관 관련 요인, 환경 노출, 유전적 소인 등의 요인에 기인하는 것으로 여겨지고 있습니다. 치료용 핵약은 종양 부하 감소, 증상 완화, 환자의 삶의 질 향상에 기여하는 표적 지향적이고 효과적인 치료 옵션을 제공함으로써 암 치료에 있어 매우 중요한 역할을 합니다. 예를 들어, 2024년 2월 유엔 기구인 세계보건기구(WHO)가 발표한 예측에 따르면, 2050년까지 3,500만 명 이상의 암 환자가 새로 진단될 것으로 예상되며, 이는 2022년 추정 환자 수 2,000만 명에 비해 77% 증가한 수치입니다. 그 결과, 암 유병률 증가가 치료용 핵의약품 시장의 성장에 기여하고 있습니다.

치료용 핵의학 시장에서 사업을 전개하는 주요 기업들은 새로운 임상적 증거를 통해 다발성 종양 치료의 가능성을 강조하며 표적 방사선 치료 솔루션을 추진하고 있습니다. 이러한 노력은 혁신 파이프라인 강화, 치료 적응증 확대, 차세대 방사성의약품 도입 가속화에 초점을 맞추었습니다. 예를 들어, 2025년 미국 소재 임상 단계 바이오 제약사 액티늄 파마슈티컬스(Actinium Pharmaceuticals)는 자사의 첫 번째 액티늄225 기반 방사선 치료제 ATNM-400에 대한 새로운 임상 데이터를 발표하며 비소세포폐암(NSCLC)을 포함한 여러 암종에 대한 잠재적 효능을 입증했습니다. 비소세포폐암(NSCLC)을 포함한 여러 암종에 대한 잠재적 효능을 입증했습니다. 본 데이터는 'AACR-NCI-EORTC 분자 표적 및 암 치료 국제 컨퍼런스'에서 발표되었습니다. ATNM-400은 고정밀 표적화를 통한 강력한 알파 입자 요법을 실현하도록 설계되어 다양한 고형암에 대한 혁신적인 치료 플랫폼으로서의 가능성을 입증하고 있습니다. 이러한 발전은 환자 치료 결과를 개선하고 새로운 시장 기회를 창출하기 위해 액티늄 방사선 치료의 임상 적용 범위를 확대하는 데 업계가 집중하고 있음을 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Therapeutic nuclear drugs are a category of medications that use radioactive substances to treat diseases, especially cancer. These drugs employ targeted radiopharmaceuticals that attach to cancer cells and deliver therapeutic levels of radiation directly to them, helping destroy malignant cells while limiting damage to nearby healthy tissue.

The primary types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223 is a therapeutic nuclear drug mainly used for treating prostate cancer that has metastasized to the bones. These drugs are distributed through channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and they are used for applications including thyroid disorders, bone metastasis, lymphoma, and others.

Tariffs have impacted the therapeutic nuclear drug market by increasing costs associated with imported radioactive isotopes, specialized manufacturing equipment, and shielding materials. Hospital-based nuclear medicine departments and cancer research institutes in regions such as North America and Europe are particularly affected due to dependence on cross-border isotope supply chains. These cost pressures can delay treatment availability and raise operational expenses. However, tariffs have also encouraged domestic isotope production, strengthened local supply chains, and stimulated investments in regional nuclear drug manufacturing capabilities.

The therapeutic nuclear drug market research report is one of a series of new reports from The Business Research Company that provides therapeutic nuclear drug market statistics, including therapeutic nuclear drug industry global market size, regional shares, competitors with a therapeutic nuclear drug market share, detailed therapeutic nuclear drug market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic nuclear drug industry. This therapeutic nuclear drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing cancer prevalence, early adoption of iodine-131 in thyroid disorders, limited availability of targeted oncology therapies, growth of nuclear medicine departments, rising clinical acceptance of radiopharmaceuticals.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to development of novel therapeutic isotopes, expansion of precision oncology approaches, increasing investment in nuclear medicine infrastructure, growing clinical trials for radioligand therapies, favorable regulatory approvals for targeted nuclear drugs. Major trends in the forecast period include rising adoption of targeted radiopharmaceutical therapies, increasing use of lutetium-177 and alpha-emitting isotopes, growth in cancer-specific nuclear drug applications, expansion of combination therapies with nuclear drugs, strengthening focus on safety dosimetry and regulatory compliance.

The rising prevalence of cancer is anticipated to drive the growth of the therapeutic nuclear drug market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells. The increasing occurrence of cancer is attributed to factors such as improved detection and diagnostic capabilities, lifestyle-related influences, environmental exposures, and genetic predispositions. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted and effective therapeutic options that help reduce tumor burden, relieve symptoms, and enhance patients' quality of life. For example, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, it is projected that more than 35 million new cancer cases will be diagnosed by 2050, representing a 77% increase compared with the estimated 20 million cases recorded in 2022. As a result, the increasing prevalence of cancer is contributing to the growth of the therapeutic nuclear drug market.

Major companies operating in the therapeutic nuclear drug market are advancing targeted radiotherapy solutions by highlighting novel multi-tumor treatment potential through emerging clinical evidence. These initiatives are focused on strengthening innovation pipelines, broadening therapeutic indications, and accelerating the adoption of next-generation radiopharmaceuticals. For instance, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new clinical data for ATNM-400, its first-in-class Actinium-225-based radiotherapy, demonstrating potential efficacy across multiple tumor types, including non-small cell lung cancer (NSCLC). The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, supporting its potential as a transformative treatment platform for a range of solid tumors. This development underscores the industry's emphasis on expanding the clinical scope of actinium-based radiotherapies to improve patient outcomes and unlock new market opportunities.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals seeks to strengthen its therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which is designed to target bone metastases and osteosarcoma. QSAM Biosciences is a US-based biotechnology company dedicated to the development of next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Therapeutic Nuclear Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The therapeutic nuclear drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types
• 2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
• 3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
• Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.A.; Jubilant DraxImage Inc.; Mallinckrodt Pharmaceuticals PLC; The Bracco Group; Lantheus Medical Imaging Inc.; Piramal Group; Curium Pharmaceuticals; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Eckert & Ziegler; Telix Pharmaceuticals Limited; International Isotopes inc.; Orano SA; Q BioMed Inc.; Molecular Targeting Technologies Inc; Medi-Radiopharma Co. Ltd.; Actinium Pharmaceuticals; Fusion Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Therapeutic Nuclear Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Therapeutic Nuclear Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Therapeutic Nuclear Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Therapeutic Nuclear Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Radiopharmaceutical Therapies
  • 4.2.2 Increasing Use Of Lutetium-177 And Alpha-Emitting Isotopes
  • 4.2.3 Growth In Cancer-Specific Nuclear Drug Applications
  • 4.2.4 Expansion Of Combination Therapies With Nuclear Drugs
  • 4.2.5 Strengthening Focus On Safety, Dosimetry, And Regulatory Compliance

5. Therapeutic Nuclear Drug Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cancer Treatment Centers
• 5.3 Ambulatory Surgical Centers (Ascs)
• 5.4 Cancer Research Institutes
• 5.5 Nuclear Medicine Clinics

6. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Therapeutic Nuclear Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Therapeutic Nuclear Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Therapeutic Nuclear Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Therapeutic Nuclear Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Therapeutic Nuclear Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Therapeutic Nuclear Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Therapeutic Nuclear Drug Market Segmentation

• 9.1. Global Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Radium-223, Lutetium-177, Iodine-131, Other Types
• 9.2. Global Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes
• 9.3. Global Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Thyroid, Bone Metastasis, Lymphoma, Other Applications

10. Therapeutic Nuclear Drug Market Regional And Country Analysis

• 10.1. Global Therapeutic Nuclear Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Therapeutic Nuclear Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Therapeutic Nuclear Drug Market

• 11.1. Asia-Pacific Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Therapeutic Nuclear Drug Market

• 12.1. China Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Therapeutic Nuclear Drug Market

• 13.1. India Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Therapeutic Nuclear Drug Market

• 14.1. Japan Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Therapeutic Nuclear Drug Market

• 15.1. Australia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Therapeutic Nuclear Drug Market

• 16.1. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Therapeutic Nuclear Drug Market

• 17.1. South Korea Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Therapeutic Nuclear Drug Market

• 18.1. Taiwan Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Therapeutic Nuclear Drug Market

• 19.1. South East Asia Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Therapeutic Nuclear Drug Market

• 20.1. Western Europe Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Therapeutic Nuclear Drug Market

• 21.1. UK Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Therapeutic Nuclear Drug Market

• 22.1. Germany Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Therapeutic Nuclear Drug Market

• 23.1. France Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Therapeutic Nuclear Drug Market

• 24.1. Italy Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Therapeutic Nuclear Drug Market

• 25.1. Spain Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Therapeutic Nuclear Drug Market

• 26.1. Eastern Europe Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Therapeutic Nuclear Drug Market

• 27.1. Russia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Therapeutic Nuclear Drug Market

• 28.1. North America Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Therapeutic Nuclear Drug Market

• 29.1. USA Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Therapeutic Nuclear Drug Market

• 30.1. Canada Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Therapeutic Nuclear Drug Market

• 31.1. South America Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Therapeutic Nuclear Drug Market

• 32.1. Brazil Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Therapeutic Nuclear Drug Market

• 33.1. Middle East Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Therapeutic Nuclear Drug Market

• 34.1. Africa Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Therapeutic Nuclear Drug Market Regulatory and Investment Landscape

36. Therapeutic Nuclear Drug Market Competitive Landscape And Company Profiles

• 36.1. Therapeutic Nuclear Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Therapeutic Nuclear Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Therapeutic Nuclear Drug Market Company Profiles
  • 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Therapeutic Nuclear Drug Market Other Major And Innovative Companies

• Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

38. Global Therapeutic Nuclear Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Therapeutic Nuclear Drug Market

40. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies

• 40.1 Therapeutic Nuclear Drug Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Therapeutic Nuclear Drug Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Therapeutic Nuclear Drug Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer